Clinical Trial Details
| Trial ID: | L4205 |
| Source ID: | NCT00671424 |
| Associated Drug: | Hydrochlorothiazide (Hctz) |
| Title: | A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: Hydrochlorothiazide (HCTZ)|DRUG: Remogliflozin etabonate (GSK189075)|DRUG: Furosemide |
| Outcome Measures: | Primary: Serum sodium and potassium concentrations:, baseline, Day 3, and Days 9-15 | Secondary: adverse events:, each visit|Physical Exam:, screening,Days -1,15,follow-up|ECG & vital signs:, Days -1,3,8,9,14,15,follow-up|Clinical labs:screening:, Days -1,3,8-15,follow-up|blood pressure:, days 7,13|urine labs:, Days 7,8,9,13,14|weight:, Days -1,3,4,9,10,15 |
| Sponsor/Collaborators: | Sponsor: GlaxoSmithKline |
| Gender: | MALE |
| Age: | ADULT |
| Phases: | PHASE1 |
| Enrollment: | 48 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT |
| Start Date: | 2008-03 |
| Completion Date: | 2008-05 |
| Results First Posted: | |
| Last Update Posted: | 2012-03-19 |
| Locations: | GSK Investigational Site, Columbus, Ohio, 43212, United States |
| URL: | https://clinicaltrials.gov/show/NCT00671424 |
